Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent - PubMed (original) (raw)
Comparative Study
. 2001 Oct 11;345(15):1098-104.
doi: 10.1056/NEJMoa011110.
Affiliations
- PMID: 11596589
- DOI: 10.1056/NEJMoa011110
Free article
Comparative Study
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
J Keane et al. N Engl J Med. 2001.
Free article
Abstract
Background: Infliximab is a humanized antibody against tumor necrosis factor alpha (TNF-alpha) that is used in the treatment of Crohn's disease and rheumatoid arthritis. Approximately 147,000 patients throughout the world have received infliximab. Excess TNF-alpha in association with tuberculosis may cause weight loss and night sweats, yet in animal models it has a protective role in the host response to tuberculosis. There is no direct evidence of a protective role of TNF-alpha in patients with tuberculosis.
Methods: We analyzed all reports of tuberculosis after infliximab therapy that had been received as of May 29, 2001, through the MedWatch spontaneous reporting system of the Food and Drug Administration.
Results: There were 70 reported cases of tuberculosis after treatment with infliximab, for a median of 12 weeks. In 48 patients, tuberculosis developed after three or fewer infusions. Forty of the patients had extrapulmonary disease (17 had disseminated disease, 11 lymph node disease, 4 peritoneal disease, 2 pleural disease, and 1 each meningeal, enteric, paravertebral, bone, genital, and bladder disease). The diagnosis was confirmed by a biopsy in 33 patients. Of the 70 reports, 64 were from countries with a low incidence of tuberculosis. The reported frequency of tuberculosis in association with infliximab therapy was much higher than the reported frequency of other opportunistic infections associated with this drug. In addition, the rate of reported cases of tuberculosis among patients treated with infliximab was higher than the available background rates.
Conclusions: Active tuberculosis may develop soon after the initiation of treatment with infliximab. Before prescribing the drug, physicians should screen patients for latent tuberculosis infection or disease.
Comment in
- Tuberculosis and treatment with infliximab.
Lim WS, Powell RJ, Johnston ID. Lim WS, et al. N Engl J Med. 2002 Feb 21;346(8):623-6. doi: 10.1056/NEJM200202213460815. N Engl J Med. 2002. PMID: 11856805 No abstract available. - Tuberculosis and treatment with infliximab.
Riminton S, Pearce N, Antony B. Riminton S, et al. N Engl J Med. 2002 Feb 21;346(8):623-6. N Engl J Med. 2002. PMID: 11859879 No abstract available. - Tuberculosis and treatment with infliximab.
Zhang Z, Correa H, Bégué RE. Zhang Z, et al. N Engl J Med. 2002 Feb 21;346(8):623-6. N Engl J Med. 2002. PMID: 11859880 No abstract available. - Tuberculosis and treatment with infliximab.
Myers A, Clark J, Foster H. Myers A, et al. N Engl J Med. 2002 Feb 21;346(8):623-6. N Engl J Med. 2002. PMID: 11859881 No abstract available. - Tuberculosis and treatment with infliximab.
De Rosa FG, Bonora S, Di Perri G. De Rosa FG, et al. N Engl J Med. 2002 Feb 21;346(8):623-6. N Engl J Med. 2002. PMID: 11859882 No abstract available. - Treatment of latent tuberculosis infection.
De Rosa FG, Craven DE. De Rosa FG, et al. N Engl J Med. 2003 Mar 27;348(13):1292-3; author reply 1292-3. N Engl J Med. 2003. PMID: 12661576 No abstract available. - [Tuberculosis during treatment with TNF-blockers].
Kneitz C. Kneitz C. Z Rheumatol. 2013 Feb;72(1):4. doi: 10.1007/s00393-013-1153-6. Z Rheumatol. 2013. PMID: 23392596 German. No abstract available.
Similar articles
- Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.
Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM. Mohan AK, et al. Clin Infect Dis. 2004 Aug 1;39(3):295-9. doi: 10.1086/421494. Epub 2004 Jul 16. Clin Infect Dis. 2004. PMID: 15306993 - Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.
Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Slifman NR, et al. Arthritis Rheum. 2003 Feb;48(2):319-24. doi: 10.1002/art.10758. Arthritis Rheum. 2003. PMID: 12571839 - Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Gómez-Reino JJ, et al. Arthritis Rheum. 2003 Aug;48(8):2122-7. doi: 10.1002/art.11137. Arthritis Rheum. 2003. PMID: 12905464 - Serious infections associated with anticytokine therapies in the rheumatic diseases.
Giles JT, Bathon JM. Giles JT, et al. J Intensive Care Med. 2004 Nov-Dec;19(6):320-34. doi: 10.1177/0885066604267854. J Intensive Care Med. 2004. PMID: 15523118 Review. - How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I. Ferkolj I. J Physiol Pharmacol. 2009 Dec;60 Suppl 7:67-70. J Physiol Pharmacol. 2009. PMID: 20388947 Review.
Cited by
- The SH3-binding domain of chorismate mutase protein of Mycobacterium tuberculosis contributes to mycobacterial virulence.
Pal R, Maurya V, Borah S, Mukhopadhyay S. Pal R, et al. iScience. 2024 Sep 27;27(11):111044. doi: 10.1016/j.isci.2024.111044. eCollection 2024 Nov 15. iScience. 2024. PMID: 39507252 Free PMC article. - Latent tuberculosis infection and biologic agents other than TNF-α inhibitors: "over-screening and over-treatment?".
Santos AP, Mello FCQ. Santos AP, et al. J Bras Pneumol. 2024 Sep 27;50(4):e20240277. doi: 10.36416/1806-3756/e20240277. J Bras Pneumol. 2024. PMID: 39356917 Free PMC article. No abstract available. - Predictors of the efficacy of vedolizumab in patients with ulcerative colitis.
Kajikawa G, Sawada T, Nakamura M, Yamamura T, Maeda K, Ishikawa E, Uetsuki K, Hirose T, Iida T, Mizutani Y, Yamao K, Ishikawa T, Furukawa K, Kawashima H. Kajikawa G, et al. Nagoya J Med Sci. 2024 Aug;86(3):407-421. doi: 10.18999/nagjms.86.3.407. Nagoya J Med Sci. 2024. PMID: 39355361 Free PMC article. - Pulmonary Manifestations of IBD: Case Report and Review of the Literature.
Herling A, Perluk TM, Freund O, Maharshak N, Cohen NA. Herling A, et al. J Clin Med. 2024 Sep 12;13(18):5401. doi: 10.3390/jcm13185401. J Clin Med. 2024. PMID: 39336887 Free PMC article. Review. - THE ROLE OF INTERFERON-GAMMA RELEASE ASSAYS IN DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION IN CHILDREN.
Šegović M, Mihatov Štefanović I, Pavić I. Šegović M, et al. Acta Clin Croat. 2023 Nov;62(3):527-538. doi: 10.20471/acc.2023.62.03.15. Acta Clin Croat. 2023. PMID: 39310695 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical